<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156819</url>
  </required_header>
  <id_info>
    <org_study_id>ALAACRC-03</org_study_id>
    <nct_id>NCT00156819</nct_id>
  </id_info>
  <brief_title>The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial</brief_title>
  <official_title>The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <brief_summary>
    <textblock>
      This research study will compare the treatment effects of three different asthma medications
      in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled
      corticosteroid. The treatments are fluticasone, montelukast (an anti?leukotriene drug), and a
      combination therapy of fluticasone and salmeterol (a long-acting beta-agonist). Fluticasone,
      montelukast, and the combination therapy of fluticasone and salmeterol (Advair DiskusÂ®) are
      all approved for the treatment of asthma. We are looking at whether the three treatments are
      equally effective for reducing the number and the severity of asthma attacks in subjects with
      mild to moderately severe asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will attempt to investigate whether asthmatic patients that are well controlled
      with low-dose twice daily inhaled corticosteroid (ICS) therapy can safely be switched to
      other modes of controller therapy without loss of asthma control. Patients demonstrating good
      control on twice-daily low-dose ICS will be randomized to one of three treatment groups:
      once-daily low-dose ICS (fluticasone), leukotriene receptor antagonist (montelukast), or
      once-daily combination therapy (fluticasone-salmeterol).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants continued fluticasone (100 microgram twice daily) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were changed to Montelukast (5 or 10 mg each night).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone plus salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone</intervention_name>
    <description>fluticasone (100 microgram twice daily) treatment</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Fluticasone plus salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>Montelukast (5 or 10 mg each night).</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Fluticasone plus salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone plus salmeterol</intervention_name>
    <description>fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Fluticasone plus salmeterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physician-diagnosed asthma

          -  age 6 or older

          -  pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted

          -  beta-agonist reversibility OR airways hyperreactivity by methacholine challenge

          -  Juniper Asthma Control Score of 1.5 or greater if not on daily controller

          -  good current health

        Exclusion Criteria:

          -  current or past smoking (greater than 20 pack-years)

          -  chronic or current oral steroid therapy

          -  pregnancy, lack of effective contraception (when appropriate), lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Anthonisen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Winnipeg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemour's Childrens Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami (and University of South Florida in Tampa)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Consortium (Northwestern, Univ. of Chicago, Univ. of Illinois)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri at Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Hospital (and North Shore Hospital)</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Consortium (New York Univ. and Columbia Univ.)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New England Consortium (Univ. of Vermont and other locations)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrials.org/alaacrc</url>
    <description>American Lung Association Asthma Clinical Research Centers</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>November 4, 2015</results_first_submitted>
  <results_first_submitted_qc>November 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2015</results_first_posted>
  <last_update_submitted>November 4, 2015</last_update_submitted>
  <last_update_submitted_qc>November 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <keyword>Asthma</keyword>
  <keyword>Asthma Control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone</title>
          <description>Participants continued fluticasone (100 microgram twice daily) treatment.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="P2">
          <title>Montelukast</title>
          <description>Participants were changed to Montelukast (5 or 10 mg each night).
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="P3">
          <title>Fluticasone Plus Salmeterol</title>
          <description>Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone</title>
          <description>Participants continued fluticasone (100 microgram twice daily) treatment.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="B2">
          <title>Montelukast</title>
          <description>Participants were changed to Montelukast (5 or 10 mg each night).
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="B3">
          <title>Fluticasone Plus Salmeterol</title>
          <description>Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="165"/>
            <count group_id="B4" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="14.6"/>
                    <measurement group_id="B2" value="32.4" spread="15.4"/>
                    <measurement group_id="B3" value="30.8" spread="14.9"/>
                    <measurement group_id="B4" value="30.8" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure</title>
        <description>The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Participants continued fluticasone (100 microgram twice daily) treatment.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
          </group>
          <group group_id="O2">
            <title>Montelukast</title>
            <description>Participants were changed to Montelukast (5 or 10 mg each night).
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Plus Salmeterol</title>
            <description>Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone</title>
          <description>Participants continued fluticasone (100 microgram twice daily) treatment.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="E2">
          <title>Montelukast</title>
          <description>Participants were changed to Montelukast (5 or 10 mg each night).
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone Plus Salmeterol</title>
          <description>Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
fluticasone: fluticasone (100 microgram twice daily) treatment
montelukast: Montelukast (5 or 10 mg each night).
Fluticasone plus salmeterol: fluticasone (100 microgram) plus salmeterol (50 microgram) each night</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Suffered concussion while snowboarding.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction to peanuts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Allergic reaction to Bactim</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Elbow sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Drop in peak flow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Partial right knee replacement surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Tonsilectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomitting</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Gastrointestinal distress</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarsness/ dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Sinisitis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Viral respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory inflammation</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Razan Yasin</name_or_title>
      <organization>Johns Hopkins Center for Clinical Trials</organization>
      <phone>443-287-5796</phone>
      <email>ryasin1@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

